Santen gains China NMPA approval of Tapcom

7 April 2025

Japanese ophthalmology company Santen Pharmaceutical (TYO: 4536) said it has earned approval from Chinese regulatory, the National Medical Products Administration (NMPA), for its glaucoma and ocular hypertension treatment Tapcom (tafluprost + timolol), previously known with the development code STN1011101.

The number of people living with glaucoma worldwide is expected to reach an estimated 111.8 million in 2040.

The “Chinese Glaucoma Guidelines 2022” states that when monotherapy fails to achieve the target IOP, a combination of drugs with different mechanisms of action may be used. A fixed combination is more convenient to use and has better compliance, making it a more economical therapy. In comparison with the separate use of both components, a fixed combination is recommended when available.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK